Journal of NeuroInterventional Surgery · 2012 · 118 citations · 23 references
PharmacyPharmacotherapySurgeryCardiovascular PharmacotherapyCerebrovascular SurgeryVascular SurgeryAntiplatelet TherapyAntithrombotic TherapyThromboembolism PreventionThrombosisThrombosis ManagementThrombosis PreventionAntithrombotic Therapy After Stent ImplantationCerebral Arterial StenosisClopidogrel ResistanceDural Arteriovenous Fistula ManagementDural Arteriovenous Fistula TreatmentEndovascular Stroke TreatmentNeurointerventional Antiplatelet TherapyStent Thrombosis Prevention
INTRODUCTION: Dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine (eg, clopidogrel) prevents stent related thromboembolic events in cardiac patients and is frequently utilized during neurointerventional surgery. However, recent data suggest that many patients exhibit clopidogrel resistance. Prasugrel-a newer thienopyridine-lowers the rate of cardiac stent thromboses in clopidogrel non-responders but a paucity of data exist regarding its safety and efficacy in neurointerventional surgery. METHODS: All patients undergoing neurointerventional surgery by a single interventionalist (CJM) over a 20 month period were retrospectively identified. Charts were reviewed for pre- and post-procedural DAPT regimens, pre-procedural coagulation parameters and procedural complications. RESULTS: 76 patients received pre- and post-procedural DAPT for endovascular treatment of an intracerebral aneurysm, dural arteriovenous fistula or intra/extracranial arterial stenosis. 51 patients underwent 55 total procedures and were treated with aspirin/clopidogrel; 25 patients underwent 31 total procedures and were treated with aspirin/prasugrel. Those patients who received aspirin/prasugrel DAPT were identified pre-procedurally to be clopidogrel non-responders. Both treatment groups had a similar percentage of patients undergoing aneurysm coiling, stent assisted aneurysm coiling, aneurysm Onyx embolization, aneurysm pipeline embolization device treatment, extra/intracranial carotid artery angioplasty and stenting, and dural arteriovenous fistula coil embolization. A total of eight (9.3%) hemorrhagic complications were observed, two (3.6%) in the aspirin/clopidogrel group and six (19.4%) in the aspirin/prasugrel group (p=0.02). No differences were noted in hemorrhage rates for each procedure between treatment groups, nor were there any differences in thrombotic complications between groups. CONCLUSION: Our results suggest that DAPT with aspirin/prasugrel may predispose to a higher risk of hemorrhage during neurointerventional surgery compared with DAPT with aspirin/clopidogrel.
23
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
Steven R. Steinhubl, Peter B. Berger, J. Tift Mann et al. · JAMA · 2002 · 3.1K citations
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article
Sidney C. Smith, Ted Feldman, John W. Hirshfeld et al. · Circulation · 2006 · 2.2K citations
Medicine, Cardiology, Surgery +13